Social Media Ideas for Abbv

ABIVAX Société Anonyme (ABVX) Discusses Positive Phase III ABTECT Trial Results for Obefazimod in Ulcerative Colitis - S...

ABIVAX Société Anonyme (ABVX) Discusses ABTECT Maintenance Part 2 Results and Updated Obefazimod Safety and Efficacy Dat...

<![CDATA[AbbVie to Acquire Apogee Therapeutics in $10 Billion Deal]]>

Dividend Kings In Focus: AbbVie

Updated on July 9th, 2026 by Josh Arnold We believe that long-term investors should focus on the highest-quality dividend-growth stocks. These are companies with long histories of...

Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst

Is ABIVAX Société Anonyme (ABVX) A Good Stock To Buy Now?

Is AbbVie a Buy After Its Purchase of Apogee?

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

<![CDATA[Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion]]>

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster” sal...

StockWatch: New UC Data Sparks Smoother Sailing for Abivax

Less than a month after its stock roller-coastered on safety signals associated with its late-stage ulcerative colitis (UC) drug candidate obefazimod, shares of Abivax (Euronext Pa...

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer admin Thu, 05/28/2026 - 11:51 Steady progress across the board today, with new appro...

AbbVie to Acquire Apogee Therapeutics for $10.9B

Apogee’s lead candidate zumilokibart, an IL-13 inhibitor also called APG777, is a long-acting treatment that, according to the company, holds “pipeline-in-a-product potential” beca...

AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment

Abivax: Downgrading To 'Hold' As NDA Obefazimod Still Underway Despite Major Safety Risks

Abivax rebounds from stock drop with safety data for much-hyped colitis prospect

Abivax has recovered from a dent in its share price after unveiling fresh safety data that appeared to ease investors’ concerns with its ulcerative colitis prospect.

AbbVie Oncology

AbbVie Oncology Anonymous (not verified) Fri, 07/03/2026 - 06:06 field_thread_url https://cafepharma.com/boards/threads/abbvie-oncology.699564/...

Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial

Abivax has raised the efficacy bar in ulcerative colitis, linking obefazimod to a 40%, placebo-adjusted jump in clinical remission rates in a phase 3 trial. But the share price of...

AbbVie’s $11B Apogee Acquisition Brings an Eczema Drug With an Edge

Apogee Therapeutics brings AbbVie a long-acting antibody ready for Phase 3 testing in atopic dermatitis, also called eczema. This therapy’s pipeline in a product potential includes...

Two Paths to Growth: Johnson & Johnson vs AbbVie

AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect

AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 billion. The deal will give AbbVie control of a late-phase eczema drug candidate that could pose a threat to Eli Lilly...

Abivax stock reverses course, trades down 40% despite positive ulcerative colitis trial

AbbVie Oncology

AbbVie Oncology Anonymous (not verified) Fri, 07/10/2026 - 09:11 field_thread_url https://cafepharma.com/boards/threads/abbvie-oncology.699564/...

Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?

For a solid yield and strong upside potential, this pharmaceutical stock is worth considering.

StockWatch: Abivax Survives a Roller Coaster Week

Abivax’s stock plummeted after analysts from Jefferies, Morgan Stanley, Truist Securities, and Wedbush Securities raised as a safety concern a portion of data showing malignancies...